This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Posiphen
- DrugBank Accession Number
- DB15317
- Background
Posiphen is under investigation in clinical trial NCT02925650 (Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Posiphen (DB15317)
- Weight
- Average: 337.423
Monoisotopic: 337.179026993 - Chemical Formula
- C20H23N3O2
- Synonyms
- (+)-Posiphen
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol Posiphen may increase the bradycardic activities of Acebutolol. Acetylcholine The risk or severity of adverse effects can be increased when Posiphen is combined with Acetylcholine. Aclidinium Posiphen may increase the neuromuscular blocking activities of Aclidinium. Amantadine The therapeutic efficacy of Amantadine can be decreased when used in combination with Posiphen. Amifampridine The risk or severity of adverse effects can be increased when Posiphen is combined with Amifampridine. Amitriptyline The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Posiphen. Amobarbital The therapeutic efficacy of Amobarbital can be decreased when used in combination with Posiphen. Amoxapine The therapeutic efficacy of Amoxapine can be decreased when used in combination with Posiphen. Anisotropine methylbromide The therapeutic efficacy of Anisotropine methylbromide can be decreased when used in combination with Posiphen. Aripiprazole The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Posiphen. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Z0O4TJ588O
- CAS number
- 116839-68-0
- InChI Key
- PBHFNBQPZCRWQP-AZUAARDMSA-N
- InChI
- InChI=1S/C20H23N3O2/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14/h4-10,13,18H,11-12H2,1-3H3,(H,21,24)/t18-,20+/m0/s1
- IUPAC Name
- (3aR,8aS)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-phenylcarbamate
- SMILES
- CN1CC[C@@]2(C)[C@@H]1N(C)C1=CC=C(OC(=O)NC3=CC=CC=C3)C=C21
References
- General References
- Not Available
- External Links
- ChemSpider
- 9424375
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Terminated Treatment Alzheimer's Disease (AD) / Amnestic Mild Cognitive Impairment (aMCI) 1 1, 2 Completed Treatment Alzheimer's Disease (AD) 1 1, 2 Completed Treatment Alzheimer's Disease (AD) / Parkinson's Disease (PD) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0509 mg/mL ALOGPS logP 3.38 ALOGPS logP 4.25 Chemaxon logS -3.8 ALOGPS pKa (Strongest Acidic) 12.86 Chemaxon pKa (Strongest Basic) 6.58 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 44.81 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 99.96 m3·mol-1 Chemaxon Polarizability 37.5 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at May 20, 2019 15:13 / Updated at June 12, 2020 16:53